Smart Pharma Token (SMPT) Debuts Its Initial Listing On IDAX: Global Blockchain Cryptocurrencies Trading Exchange Platform
July 11 2019 - 8:00AM
Business Wire
Smart Pharma Group, a subsidiary group of Aptorum Group Limited
(Nasdaq: APM), is excited to share that our Smart Pharma Token
(“SMPT token”), traded publicly for the first time at 2:00 pm, 10
July 2019 (UTC+8:00), on IDAX (https://www.idax.pro/). Trading is
initially open for trading across SMPT/BTC (Bitcoin) and SMPT/ETH
(Ethereum) trading pairs only; and SMPT debuted at the equivalent
price of about US$0.025 per token. As at 12:00 am, 11 July 2019
(UTC+8:00), the token is trading in Dollar terms at about US$0.0253
per token
Based on valuation methodologies and assumptions described in
the Smart Pharma Token (SMPT) Token Economy Appendix
(https://www.smtph.io/doc/token-paper.pdf?v=2.2), the debut price
of US$0.025 and referenced trading price of US$0.0253 per token,
currently values the underlying repurposed and new drug discovery
platform, Smart-ACT™ between US$169 million and US$171 million.
Since the tokens are not a liquid market, this valuation is merely
an estimate based upon the prices noted herein and we have not made
any independent verification of such valuation; there is no
guarantee that such valuation will be maintained.
More details on SMPT and Smart-ACT™ are provided below.
About the SMPT token:
The SMPT token is an ERC-1404 security compliant token with
ERC-20 and ERC233 compliance on the Ethereum blockchain. SMPT
tokenizes rights to a portion of the royalty income derived from
the eventual commercialization of intellectual property rights of
drug candidates to be discovered under our Smart-ACT™ platform.
About the Smart-ACT™ platform:
The Smart-ACT™ platform is a repurposed and new drug discovery
platform launched by the Smart Pharma Group which intends to
revolutionize drug discovery, repurposing and repositioning. In the
forthcoming developments, Smart Pharma Group would include the
incorporation of blockchain technology into the drug development
and discovery processes, initially through the adoption of the SMPT
token as the first step. We believe that blockchain technology will
significantly increase data transparency and bring distributed
power from participants worldwide to co-develop and evolve our next
Smart-ACT™ platform technology.
Smart Pharma Group recognizes that blockchain-based technology
will continue to play an important role in pharmaceutical
development and also has the capability to foster community-based
ecosystems of passionate and like-minded people in revolutionizing
the drug discovery industry who would like to be an integral part
of the process around projects.
For further information, please join the discussions on our
social media platforms which can be accessed as follows.
Website: https://www.smtph.com
Telegram: https://t.me/Aenco
LinkedIn: https://www.linkedin.com/company/Aenco
Medium: https://medium.com/@Aencoin
Twitter: https://twitter.com/Aencoin
Facebook: www.facebook.com/Aencoin
Discord: https://discord.gg/NXpFcKQ
YouTube: YouTube.Aencoin.com
About Smart Pharma Group
Smart Pharma Group includes Smart Pharmaceutical Limited
Partnership, a limited partnership registered in Seychelles, and
its general partner, SMTPH Limited, an international business
company incorporated under the laws of Seychelles. SMTPH Limited
and its subsidiaries are indirectly wholly owned by Aptorum Group
Limited.
Disclaimer
The SMPT tokens are currently not offered for sale to citizens,
nationals, residents (tax or otherwise), green card holders and/or
companies domiciled in the following: (a) the United States of
America; (b) Singapore; (c) Hong Kong (except for Professional
Investors); (d) the People’s Republic of China; (e) Samoa, (f)
Seychelles, (g) sanctioned countries under the OFAC and (h) any
other jurisdiction which prohibits the possession, dissemination or
communication of the Whitepaper.
Statements, estimates and financial information contained
hereunder, on our website http://www.SMTPH.com, made in any
announcements or in any place accessible by the public and oral
statements that may be made by the Smart Pharma Group may
constitute forward-looking statements. Smart Pharma Group disclaims
any responsibility to update any of these forward-looking
statements or publicly announce any revisions to these
forward-looking statements to reflect future developments, events
or circumstances, even if new information becomes available or
other events occur in the future.
This communication shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of securities in any jurisdiction in which the offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such
jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190711005283/en/
For Aptorum Group Limited Investor Relations and
Media Tel: +852 2117 6611
Email: investor.relations@aptorumgroup.com
Website: http://www.aptorumgroup.com
For Smart Pharma Information Request Tel:
+852 2117 6611 Email: info@smtph.com
Website: http://www.smtph.com
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024